Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on brain-targeted therapeutics, has announced significant progress in its Phase IIa feasibility trial for ONP-002, a potential treatment for mild traumatic brain injury (mTBI) or concussion. The company has dosed nine participants across three active clinical sites in Australia: Alfred Health, Mackay, and Royal Adelaide Hospital. This development underscores the ongoing efforts to evaluate the safety and efficacy of ONP-002, which utilizes the company's proprietary intranasal delivery platform.
The announcement comes alongside updates on regulatory and listing matters. Oragenics has received responses from the U.S. Food and Drug Administration (FDA) regarding its Type B meeting request briefing package, which was submitted in July 2026. The company is currently reviewing the FDA's feedback and remains focused on submitting an Investigational New Drug (IND) application by the end of 2026. This step is crucial for advancing ONP-002 into U.S. clinical trials, with a Phase 2b study planned to follow the Australian trials.
In parallel, Oragenics disclosed that it received a deficiency letter from NYSE American on Aug. 26, 2026, citing non-compliance with stockholders' equity requirements under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. The company has 45 days from receipt of the letter to submit a plan to regain compliance. Oragenics intends to submit the plan within the required timeframe. If accepted, the plan would allow the company to maintain its listing during a cure period, subject to periodic review, with a compliance deadline of Feb. 25, 2028.
These updates highlight the dual challenges facing clinical-stage biotech companies: advancing promising science through rigorous regulatory pathways while maintaining financial and listing standards. Oragenics' progress in the Phase IIa trial is a positive indicator for the potential of ONP-002, which could address a significant unmet medical need in concussion management. Current treatments for mTBI are largely supportive, and a targeted therapeutic could be a game-changer for the millions affected annually.
The company's intranasal delivery platform is also being explored for other neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders, which broadens its potential impact. As Oragenics navigates the FDA's feedback and works toward its IND submission, the outcome will be closely watched by investors and the medical community. The NYSE American listing issue adds a layer of complexity, but the company's proactive approach to compliance suggests a commitment to overcoming these hurdles.
For more details on the trial and company updates, visit the press release at https://nnw.fm/HZ5fb.
